GET DAILY SIGNALSCVS Health (CVS) Stabilizes Near $90 After +5% Monthly Gain and -13% Quarterly Retreat
Key Takeaways
- CVS Health shares were trading around $90 in late October, a modest single-digit advance of roughly 5% over the trailing 30 days after a pullback toward the mid-$80s.
- The stock remains well below its mid-summer levels, having declined roughly 13% over the past three months.
- CVS Health operates an integrated healthcare model spanning retail pharmacy, pharmacy benefits management (Caremark), and health insurance (Aetna).
- Investor sentiment continues to hinge on medical cost trends, Medicare Advantage margins, and pharmacy reimbursement pressure.
- With the 30-day move below 10%, price action remains in a stabilization and consolidation phase rather than a sharp directional breakout.
- For deeper context on valuation and financials, explore CVS Health's Price Targets, Earnings, and Forecast pages.
- Traders seeking automated signals can explore Trending AI Robots for active strategies across thousands of tickers.
Where CVS Health Stands in the Market Right Now
CVS Health (CVS) shares closed near $90 as October drew to a close, reflecting a period of relative calm after a more volatile stretch earlier in the year. Over the trailing 30 days, the stock edged higher by roughly 5%, recovering from the mid-$80s lows it touched in late September. That stabilization, however, follows a broader downward drift: measured over the trailing three months, the stock has retreated approximately 13%, with shares moving from above $104 in late July to the low-$90s range.
This divergence between the short-term and medium-term picture is central to the current setup. In the near term, the stock has found footing and begun to base around the $90 area. Over the longer window, investors are still weighing structural pressures across the healthcare-services sector, where reimbursement dynamics, benefit design changes, and utilization trends have weighed on valuations broadly. From what I see, the consolidation phase suggests the market is digesting these factors without committing to a strong direction just yet.
CVS Health's Integrated Business Model and Competitive Position
CVS Health is one of the largest integrated healthcare companies in the United States. Its operations span three complementary segments: a nationwide retail pharmacy footprint, a pharmacy benefits manager (PBM) operating under the Caremark brand, and a health-insurance arm through Aetna. The company also offers in-store and digital health services, including MinuteClinic locations, that extend its reach into primary and convenient care.
This vertical integration is a defining competitive feature. By combining pharmacy dispensing, drug-pricing negotiation, insurance administration, and care delivery under one roof, CVS Health seeks to capture value across the prescription-drug and healthcare value chain while positioning itself to manage total cost of care. The company competes with diversified healthcare and retail-pharmacy peers such as UnitedHealth Group (UNH), Cigna (CI), and Walgreens Boots Alliance (WBA). I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors follow the stock closely because its results offer a broad read on pharmacy demand, insurance utilization, and healthcare cost trends in the U.S.
Recent Developments Shaping CVS Health
Over the past month, CVS Health's shares have moved in a relatively narrow band, reflecting a market that is reassessing the company's earnings outlook rather than reacting to a single catalyst. The modest recovery from late-September lows is consistent with a stabilization in sentiment after an earlier de-rating driven by concerns about medical-cost trends in the insurance business and ongoing scrutiny of pharmacy-benefit practices.
Several recurring themes continue to shape the narrative. Elevated medical utilization and tighter Medicare Advantage margins have been a persistent focus for investors, as have questions about prescription-drug reimbursement and the competitive position of retail pharmacy. Regulatory attention on PBM pricing transparency remains a longer-running overhang for the broader industry. On the balance-sheet side, investors also continue to monitor cash-flow generation and the company's capital-allocation priorities as it manages a sizable debt load following its Aetna acquisition.
No single event defined the trailing 30 days; instead, the stock's move reflects a market gradually finding equilibrium around the $90 level after the sharper declines of the summer and early autumn.
Key Factors to Watch Through 2026
Looking ahead, several factors are likely to shape how CVS Health trades through 2026. Medical cost ratios and utilization trends within the Aetna insurance segment will remain a primary focus, as improvements or deteriorations there directly influence profitability. Medicare Advantage star ratings and reimbursement levels are another key variable, given their impact on both revenue and margins.
On the pharmacy side, investors will watch prescription volumes, generic and specialty drug pricing, and any legislative or regulatory developments affecting PBM transparency and rebate practices. The pace of the company's cost-reduction and productivity initiatives, as well as its progress on deleveraging, will also be closely monitored. Broader macro forces—including interest rates, healthcare policy changes, and consumer demand for pharmacy and clinic services—add further layers of uncertainty. These are factors to monitor rather than a basis for near-term predictions, and outcomes will ultimately depend on execution and the evolving regulatory environment. I'm watching this closely as the data unfolds.
Exploring AI-Driven Trading Strategies
In my own research process, I sometimes turn to automated tools to scan for patterns across a wide range of names. Tickeron's Trending AI Robots page offers a curated view of the platform's most relevant automated strategies. It highlights top-performing bots that monitor thousands of tickers, with options to filter by strategy, timeframe, and risk metrics. This can serve as a useful discovery tool when evaluating data-driven ideas that align with individual objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CVS in upward trend: 10-day moving average broke above 50-day moving average on October 23, 2026
The 10-day moving average for CVS crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for CVS just turned positive on October 06, 2026. Looking at past instances where CVS's MACD turned positive, the stock continued to rise in 33 of 50 cases over the following month. The odds of a continued upward trend are 66%.
Following a +2.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVS advanced for three days, in 228 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 155 of 253 cases where CVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The 10-day RSI Indicator for CVS moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 26 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVS as a result. In 55 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.
CVS moved below its 50-day moving average on October 28, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
CVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CVS's P/B Ratio (1.448) is slightly lower than the industry average of (3.380). P/E Ratio (23.626) is within average values for comparable stocks, (124.266). CVS's Projected Growth (PEG Ratio) (0.206) is slightly lower than the industry average of (0.786). CVS has a moderately high Dividend Yield (0.029) as compared to the industry average of (0.009). P/S Ratio (0.283) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating fairly steady price growth. CVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 74 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an integrated pharmacy health care provider
Industry ManagedHealthCare
Advertisement